Products/Services Used | Details | Operation |
---|---|---|
Peptide Synthesis> | 5; Hycult Biotech, Uden, Netherlands), anti-TLR4 (clone3C3, Hycult), their corresponding isotype-matched control (5 mg/ml), the Hsp70 inhibitor VER155008 (20 mM Tocris; Bio-Techne Ltd, Abingdon, UK), the HA inhibitory peptide Pep-1, the scrambled peptide control (250 mg/ml; Genscript, Oxon, UK), or human recombinant sTLR2 (250 ng/ml, low endo- toxin; R&D Systems, Minneapolis, MN) before addition of PDS or the synthetic bacterial lipopeptide Pam3-Cys-Ser-(Lys)4 HCl (250 ng/ ml; EMC microcollections, Tübingen, Germany). | Get A Quote |
Peritoneal membrane failure due to fibrosis limits the use of peritoneal dialysis (PD). Peritoneal fibrosis may potentially be induced by sterile inflammation caused by ongoing cellular stress due to prolonged exposure to PD solutions (PDS). Effective therapies to prevent this process remain to be developed. Toll-like receptors (TLRs) mediate sterile inflammation by recognizing damage-associated molecular patterns (DAMPs) released by cellular stress. We evaluated the involvement of TLRs and DAMPs in PDS-induced fibrosis models and the therapeutic potential of TLR-DAMP targeting for preventing fibrosis. A range of PDS elicited pro-inflammatory and fibrotic responses from PD patient peritoneal leukocytes, mesothe... More